Related Experiment Videos
Bismuth salts and neurotoxicity. A randomised, single-blind and controlled study
L A Noach1, J L Eekhof, L J Bour
1Department of Gastroenterology and Hepatology, Academic Medical Centre, Amsterdam, The Netherlands.
Human & Experimental Toxicology
|April 1, 1995
Summary
Colloidal bismuth subcitrate (CBS) and bismuth subnitrate (BSN) were evaluated for neurotoxicity in a study of H. pylori patients. Results indicate that normal use of these bismuth compounds does not cause clinical neurotoxic side-effects.
Area of Science:
- Gastroenterology and Hepatology
- Pharmacology and Toxicology
Background:
- Bismuth compounds like colloidal bismuth subcitrate (CBS) and bismuth subnitrate (BSN) are used for treating H. pylori infections.
- Concerns regarding potential neurotoxic side-effects of bismuth have been raised, necessitating investigation into their safety profile.
Purpose of the Study:
- To investigate the potential neurotoxic side-effects associated with the normal therapeutic use of colloidal bismuth subcitrate (CBS) and bismuth subnitrate (BSN).
Main Methods:
- A randomized, single-blind controlled study involving 66 patients with H. pylori associated gastritis.
- Patients received amoxicillin (control), BSN, or CBS for 4-8 weeks.
- Clinical assessments, electroneurography (ENG), and spectral electroencephalography (EEG) were conducted pre- and post-therapy.
Main Results:
- No clinically significant changes were observed in clinical assessments across all treatment groups.
- Electroneurography (ENG) and spectral electroencephalography (EEG) showed no relevant alterations within or between groups post-therapy.
- The study found no evidence of clinical neurotoxicity from normal use of CBS and BSN.
Conclusions:
- The normal use of colloidal bismuth subcitrate (CBS) and bismuth subnitrate (BSN) is considered safe from a clinical neurotoxicity perspective.
- These findings support the continued use of CBS and BSN in H. pylori treatment without significant neurological concerns.